When should atropine and pralidoxime be discontinued in a patient with cholinergic toxicity?

When to Discontinue Atropine and Pralidoxime in Cholinergic Toxicity

Stop atropine when full atropinization is achieved and maintained for at least 48 hours with reversal of depressed cholinesterase activity, and discontinue pralidoxime when muscle weakness resolves and no signs of poisoning recur, typically requiring 48-72 hours of observation but potentially extending up to 10 days depending on the specific organophosphate involved. 1

Atropine Discontinuation Criteria

The FDA label provides clear endpoints for atropine therapy 1:

• Maintain atropinization for at least 48 hours minimum
• Continue until depressed blood cholinesterase activity is reversed
• Full atropinization is defined as:
  • Secretions are inhibited (clear chest on auscultation)
  • Heart rate >80/min
  • Systolic blood pressure >80 mm Hg 2

Critical pitfall: Do not stop atropine prematurely even if symptoms improve initially. Fatal relapses have been reported after initial improvement, particularly with ingested organophosphates where continuing absorption from the lower bowel constitutes ongoing exposure 1.

Pralidoxime Discontinuation Criteria

Pralidoxime should be continued based on clinical response and the specific organophosphate involved:

Standard Duration

• Minimum observation period: 48-72 hours for all organophosphate poisonings 1
• Continue pralidoxime as long as signs of poisoning recur - the patient should be "titrated" with the medication 1
• Additional doses may be needed every 3-8 hours when poison has been ingested due to continuing absorption 1

Extended Duration Considerations

Recent evidence suggests much longer treatment may be necessary 3:

• Up to 10 days of oxime therapy may be required to maintain therapeutic concentrations as long as circulating poison is present
• This is particularly important for diethyl organophosphates (like parathion), which have low propensity for enzyme "aging" and may allow reactivation after several days when poison concentration drops 3
• Dimethyl organophosphates (like monocrotophos) undergo rapid aging and may not benefit from prolonged oxime therapy 4

Clinical Monitoring for Discontinuation

Stop pralidoxime when:

• Muscle weakness has resolved 1
• No recurrence of nicotinic symptoms (fasciculations, muscle weakness, respiratory muscle paralysis)
• Patient has been observed for minimum 48-72 hours without symptom recurrence 1

Important caveat: One case report demonstrated relapse of cholinergic symptoms when oximes were stopped after only one day, whereas continuous administration for six days prevented relapse 5. Another case successfully used continuous infusion at 500 mg/hr for approximately 72 hours 6.

Practical Algorithm

1. First 48 hours: Continue both atropine and pralidoxime regardless of apparent improvement
2. After 48 hours: Assess for:
   • Complete resolution of muscarinic symptoms (secretions, bronchospasm, bradycardia)
   • Resolution of nicotinic symptoms (muscle weakness, fasciculations)
   • Reversal of cholinesterase depression (if available)
3. If symptoms persist: Continue both medications, reassessing every 12-24 hours
4. If ingestion occurred: Extend observation and treatment due to risk of continued absorption
5. Consider extended pralidoxime (up to 10 days) for severe poisonings or when the specific organophosphate is unknown 3

Key Monitoring Parameters

• Clinical signs of atropinization (dry secretions, adequate heart rate/blood pressure)
• Absence of atropine toxicity (delirium, hyperthermia, muscle twitching) 1
• Resolution of muscle weakness as primary endpoint for pralidoxime
• Cholinesterase activity levels if available - can guide decision-making about oxime continuation 4

Critical warning: Generally, little is accomplished if pralidoxime is given more than 36 hours after termination of exposure, but this refers to initial administration, not discontinuation 1. Once started, continue based on clinical response rather than arbitrary time limits.